ProShare Advisors
TCRR

ProShare Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

ProShare Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,044
Closed -$56K – 2332
2021
Q4 		$56K Sell
12,044
-32
-0.3% -$200 ﹤0.01% 2275
2021
Q3 		$103K Sell
12,076
-2,695
-18% -$38.1K ﹤0.01% 1913
2021
Q2 		$242K Buy
14,771
+1,775
+14% +$35.9K ﹤0.01% 2030
2021
Q1 		$287K Buy
12,996
+2,212
+21% +$60.3K ﹤0.01% 1831
2020
Q4 		$334K Buy
+10,784
New +$273K ﹤0.01% 1543

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ProShare Advisors's TCRR Position: Q1 2022 in Review

ProShare Advisors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2022, closing a stake of 12,044 shares — an estimated $56K sold.

ProShare Advisors first reported a position in TCRR in Q4 2020 and held it in 5 quarters. The position peaked at $334K in Q4 2020. 94 funds tracked by Wall St. Rank hold TCRR as of Q1 2022.

  • ProShare Advisors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • ProShare Advisors sold 12,044 TCR2 Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $56K.
  • ProShare Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • ProShare Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $334K in Q4 2020.
  • 94 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.